Hyperfine’s Next-Gen Swoop® with Optive AI™ Gets FDA Clearance
Hyperfine’s Next-Gen Swoop® with Optive AI™ Gets FDA Clearance Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of…
Lightcast Appoints Industry Veteran Philip Binns as Chairman of the Board
–Lightcast, a pioneering life science tools company, today announced the appointment of Philip Binns as chairman of its board of directors, effective May 1, 2025. With this appointment, the Lightcast board includes one investor director each from Arch Ventures, Illumina…
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
–Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from…
Thermo Fisher Debuts Next-Gen Mass Specs at ASMS 2025
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries…
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications At the 73rd Conference on Mass Spectrometry and…
Clairity Becomes First FDA-Authorized AI for Breast Cancer Prediction
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA)De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With…
Growve Secures Majority Equity Investment led by Palm Beach Capital and Debt Financing from TCW and NMP Capital
Growve, a leader in the health and wellness industry, announced today that it has secured a majority equity investment led by Palm Beach Capital (PBC), with participation from G-Bar Ventures and NMP Capital. As part of the transaction, Growve also closed on new debt…
MaaT Pharma Submits EMA Application for Xervyteg® in GvHD
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced the submission of the Marketing Authorization Application…
Nu Skin Enterprises Appoints James Winett to Board of Directors
Nu Skin Enterprises (NUS: NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company’s board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. “Jim…
Archer Review Bridges the Preparation Gap for NCLEX Test Takers
The NCSBN has released the NCLEX pass rates for Q1 of 2025 (January – March). Compared to Q1 of 2024, NCLEX pass rates have dropped in all categories. With large scale drops in both first time test takers and with…
STEMCELL Technologies Announces Acquisition of Cellular Highways
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications…
NCCN Guidelines Now Recommend FES PET for Lobular Breast Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase…